Trial Profile
A study of fingolimod treated multiple sclerosis patients for assessment of lymphocyte count and changes in lymphocyte subsets
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- 26 Feb 2016 New trial record